• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

欧盟非法药物、酒精和烟草的社会成本:系统评价。

Social costs of illegal drugs, alcohol and tobacco in the European Union: A systematic review.

机构信息

Addictive Behaviors Unit, Clinic Hospital, Neuroscience Institute, Barcelona, Spain.

Catalon Agency of Quality and Health Evaluation, Barcelona, Spain.

出版信息

Drug Alcohol Rev. 2017 Sep;36(5):578-588. doi: 10.1111/dar.12504. Epub 2017 Mar 23.

DOI:10.1111/dar.12504
PMID:28334460
Abstract

ISSUES

Drug use accounts for one of the main disease groups in Europe, with relevant consequences to society. There is an increasing need to evaluate the economic consequences of drug use in order to develop appropriate policies. Here, we review the social costs of illegal drugs, alcohol and tobacco in the European Union.

APPROACH

A systematic search of relevant databases was conducted. Grey literature and previous systematic reviews were also searched. Studies reporting on social costs of illegal drugs, alcohol and tobacco were included. Methodology, cost components as well as costs were assessed from individual studies. To compare across studies, final costs were transformed to 2014 Euros.

KEY FINDINGS

Forty-five studies reported in 43 papers met the inclusion criteria (11 for illegal drugs, 26 for alcohol and 8 for tobacco). While there was a constant inclusion of direct costs related to treatment of substance use and comorbidities, there was a high variability for the rest of cost components. Total costs showed also a great variability. Price per capita for the year 2014 ranged from €0.38 to €78 for illegal drugs, from €26 to €1500 for alcohol and from €10.55 to €391 for tobacco.

IMPLICATIONS AND CONCLUSIONS

Drug use imposes a heavy economic burden to Europe. However, given the high existing heterogeneity in methodologies, and in order to better assess the burden and thus to develop adequate policies, standardised methodological guidance is needed. [Barrio P, Reynolds J, García-Altés A, Gual A, Anderson P. Social costs of illegal drugs, alcohol and tobacco in the European Union: A systematic review. Drug Alcohol Rev 2017;00:000-000].

摘要

问题

药物滥用是欧洲主要疾病群体之一,给社会带来相关后果。为了制定相应政策,越来越有必要评估药物使用的经济后果。在此,我们综述了欧盟非法药物、酒精和烟草的社会成本。

方法

系统检索了相关数据库。还检索了灰色文献和先前的系统评价。纳入报告非法药物、酒精和烟草社会成本的研究。从个别研究中评估方法学、成本构成和成本。为了跨研究比较,最终成本转换为 2014 年欧元。

主要发现

45 项研究报告(11 项涉及非法药物,26 项涉及酒精,8 项涉及烟草)符合纳入标准。虽然一直包括与药物使用和合并症治疗相关的直接成本,但其余成本构成部分存在很大的可变性。总成本也显示出很大的可变性。2014 年人均价格范围为非法药物 0.38 欧元至 78 欧元,酒精 26 欧元至 1500 欧元,烟草 10.55 欧元至 391 欧元。

意义和结论

药物滥用给欧洲带来了沉重的经济负担。然而,鉴于方法学上存在很大的异质性,为了更好地评估负担,从而制定适当的政策,需要有标准化的方法学指导。

相似文献

1
Social costs of illegal drugs, alcohol and tobacco in the European Union: A systematic review.欧盟非法药物、酒精和烟草的社会成本:系统评价。
Drug Alcohol Rev. 2017 Sep;36(5):578-588. doi: 10.1111/dar.12504. Epub 2017 Mar 23.
2
A rapid and systematic review of the clinical effectiveness and cost-effectiveness of topotecan for ovarian cancer.拓扑替康治疗卵巢癌的临床有效性和成本效益的快速系统评价。
Health Technol Assess. 2001;5(28):1-110. doi: 10.3310/hta5280.
3
Home treatment for mental health problems: a systematic review.心理健康问题的居家治疗:一项系统综述
Health Technol Assess. 2001;5(15):1-139. doi: 10.3310/hta5150.
4
Cost-effectiveness of using prognostic information to select women with breast cancer for adjuvant systemic therapy.利用预后信息为乳腺癌患者选择辅助性全身治疗的成本效益
Health Technol Assess. 2006 Sep;10(34):iii-iv, ix-xi, 1-204. doi: 10.3310/hta10340.
5
Clinical effectiveness, tolerability and cost-effectiveness of newer drugs for epilepsy in adults: a systematic review and economic evaluation.成人癫痫新药的临床疗效、耐受性及成本效益:一项系统评价与经济学评估
Health Technol Assess. 2005 Apr;9(15):1-157, iii-iv. doi: 10.3310/hta9150.
6
Heated tobacco products for smoking cessation and reducing smoking prevalence.加热烟草制品戒烟和降低吸烟率。
Cochrane Database Syst Rev. 2022 Jan 6;1(1):CD013790. doi: 10.1002/14651858.CD013790.pub2.
7
A rapid and systematic review of the clinical effectiveness and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer.对紫杉醇、多西他赛、吉西他滨和长春瑞滨在非小细胞肺癌中的临床疗效和成本效益进行的快速系统评价。
Health Technol Assess. 2001;5(32):1-195. doi: 10.3310/hta5320.
8
Intravenous magnesium sulphate and sotalol for prevention of atrial fibrillation after coronary artery bypass surgery: a systematic review and economic evaluation.静脉注射硫酸镁和索他洛尔预防冠状动脉搭桥术后房颤:系统评价与经济学评估
Health Technol Assess. 2008 Jun;12(28):iii-iv, ix-95. doi: 10.3310/hta12280.
9
Drugs for preventing postoperative nausea and vomiting in adults after general anaesthesia: a network meta-analysis.成人全身麻醉后预防术后恶心呕吐的药物:网状Meta分析
Cochrane Database Syst Rev. 2020 Oct 19;10(10):CD012859. doi: 10.1002/14651858.CD012859.pub2.
10
Strategies for enhancing the implementation of school-based policies or practices targeting risk factors for chronic disease.加强针对慢性病风险因素的校本政策或实践实施的策略。
Cochrane Database Syst Rev. 2017 Nov 29;11(11):CD011677. doi: 10.1002/14651858.CD011677.pub2.

引用本文的文献

1
Network analysis of Alcohol, Smoking and Substance Involvement Screening Test (ASSIST) 3.1 items for non-medical use of alcohol, tobacco, cannabis, prescription sedatives, prescription stimulants, and prescription opioids.针对酒精、烟草、大麻、处方镇静剂、处方兴奋剂和处方阿片类药物非医疗用途的酒精、吸烟和物质使用情况筛查测试(ASSIST)3.1项目的网络分析。
Front Psychiatry. 2025 May 16;16:1541628. doi: 10.3389/fpsyt.2025.1541628. eCollection 2025.
2
Cross- analyzing the opinions and experiences of nurses, physiotherapists, dentists, midwives, and pharmacists with respect to addictive disorder screening in primary care: A qualitative study.关于初级保健中成瘾性障碍筛查,对护士、物理治疗师、牙医、助产士和药剂师的意见与经验进行交叉分析:一项定性研究。
PLoS One. 2025 Jan 24;20(1):e0315926. doi: 10.1371/journal.pone.0315926. eCollection 2025.
3
The economic burden of smoking in Belgium: incremental healthcare costs and lost productivity.比利时吸烟造成的经济负担:增加的医疗保健成本和生产力损失。
Eur J Public Health. 2025 Feb 1;35(1):108-113. doi: 10.1093/eurpub/ckae211.
4
Harnessing the healing power of nature: a review of natural interventions in substance abuse treatment and prevention.利用大自然的治愈力量:自然干预在物质滥用治疗和预防中的作用综述。
Environ Health Prev Med. 2024;29:64. doi: 10.1265/ehpm.24-00145.
5
A mixed method study exploring similarities and differences in general and social services-specific barriers to treatment-seeking among individuals with a problematic use of alcohol, cannabis, or gambling.一项混合方法研究,旨在探讨有问题地使用酒精、大麻或赌博的个体在寻求治疗方面普遍存在的障碍和与社会服务相关的障碍之间的异同。
BMC Health Serv Res. 2024 Aug 22;24(1):970. doi: 10.1186/s12913-024-11304-5.
6
Identifying available substance use disorder screening tests feasible for use in primary care: A systematic review.确定适用于初级保健的可用物质使用障碍筛查测试:一项系统评价。
Prev Med Rep. 2024 Jan 17;38:102610. doi: 10.1016/j.pmedr.2024.102610. eCollection 2024 Feb.
7
Test characteristics of shorter versions of the Alcohol, Smoking and Substance Involvement Screening Test (ASSIST) for brief screening for problematic substance use in a population sample from Israel.以色列人群样本中用于简短筛查问题物质使用的酒精、吸烟和物质使用筛查测试(ASSIST)较短版本的测试特征。
Subst Abuse Treat Prev Policy. 2023 Oct 12;18(1):58. doi: 10.1186/s13011-023-00566-7.
8
Cross-analyzing addiction specialist and patient opinions and experiences about addictive disorder screening in primary care to identify interaction-related obstacles: a qualitative study.对成瘾专家和患者关于初级保健中成瘾障碍筛查的意见和经验进行交叉分析,以确定与互动相关的障碍:一项定性研究。
Subst Abuse Treat Prev Policy. 2023 Feb 17;18(1):12. doi: 10.1186/s13011-023-00522-5.
9
Differences in the Prevalence and Profile of DSM-IV and DSM-5 Alcohol Use Disorders-Results from the Singapore Mental Health Study 2016.DSM-IV 与 DSM-5 酒精使用障碍的患病率和特征差异——来自 2016 年新加坡心理健康研究的结果。
Int J Environ Res Public Health. 2022 Dec 24;20(1):285. doi: 10.3390/ijerph20010285.
10
Lower Strength Alcohol Products-A Realist Review-Based Road Map for European Policy Making.低浓度酒精产品——基于现实主义评论的欧洲政策制定路线图。
Nutrients. 2022 Sep 13;14(18):3779. doi: 10.3390/nu14183779.